KEAP1 and metabolic dysfunction-associated steatotic liver disease: To further investigate whether CA activates keap1/Nrf2 and inhibits NFκB via AMPK to suppress oxidative stress and inflammation in NAFLD, AMPK activator AICAR and AMPK inhibitor compound C were used as a pair in the CA-mediated action of PA-treated HepG2 cells.